[{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Autologous dendritic cell vaccine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"T Cell receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Medigene AG","highestDevelopmentStatusID":"1","companyTruncated":"Medigene \/ Medigene AG"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"TCR Immunotherapy","moa":"T-cell receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Medigene","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"TCR-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ 2seventy bio","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ 2seventy bio"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"MDG1011","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"T cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Medigene \/ National Cancer Institute"},{"orgOrder":0,"company":"Medigene","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Medigene"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TCR-T-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"MDG2011","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Medigene"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MDG1015","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MDG2021","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Medigene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"14","companyTruncated":"Medigene \/ Medigene"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MDG1015","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Medigene \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Medigene

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : MDG1015 is a first-in-class, TCR-T therapy targeting NY-ESO-1/ LAGE-1a. It is being developed for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.

                          Brand Name : MDG1015

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 05, 2024

                          Lead Product(s) : MDG1015

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration combines the respective expertise of each company with Medigene’s 3S TCR generation and WuXi Biologics’ unique anti-CD3 mAb for the treatment of cancers.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 08, 2024

                          Lead Product(s) : Gene-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : WuXi Biologics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : MDG2021, a TCR-T therapy targeting KRASG12D with HLA-A*11 being developed in combination with the Company’s PD1-41BB costimulatory switch protein, for solid tumors.

                          Brand Name : MDG2021

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 20, 2024

                          Lead Product(s) : MDG2021,PD1-41BB

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims to advance T cell receptor immunotherapies against cancer

                          Brand Name : T-cell Therapy

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 21, 2024

                          Lead Product(s) : T-cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : BioNTech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : MDG1015, a TCR-T therapy targeting NY-ESO-1/LAGE-1a, is in trials for gastric, ovarian cancers, and soft tissue sarcomas.

                          Brand Name : MDG1015

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          February 12, 2024

                          Lead Product(s) : MDG1015

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.

                          Brand Name : MDG1015

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 25, 2023

                          Lead Product(s) : MDG1015,PD1-41BB

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

                          Brand Name : MDG2011

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 18, 2023

                          Lead Product(s) : MDG2011

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The patent issued by the Japan Patent Office protecting its PD1-41BB switch receptor. Medigene's PD1-41BB costimulatory switch receptor technology was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 22, 2023

                          Lead Product(s) : TCR-T-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 02, 2023

                          Lead Product(s) : TCR-T-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Helmholtz Zentrum München

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The companies will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors in T cell-based Therapy.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 03, 2023

                          Lead Product(s) : T cell-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : National Cancer Institute

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank